-
2024-518191-31-00
Inflammatory rheumatic disease 6
-
2025-522698-13-00
Influenza, Obesity, Type 2 diabetes 6
-
2026-525211-14-00
HIV-1 4
-
2024-515978-27-00
Sepsis 11
-
2025-522140-40-00
multiple sclerosis 4
-
2025-523476-23-00
Tick-Borne Encephalitis (TBE) 4
-
2025-522756-97-00
COVID-19 and Severely Impaired B-cell Function 4
-
2024-520419-42-00
giving a commercially available vaccine to women with H 11
-
2024-516800-40-00
Infectious diseases of respiratory system (COVID-19) 4
-
2024-519876-17-00
18-64 years old volunteers with general good health 6
-
2024-513395-18-00
Healthy infants receiving a profylactic vaccine to prev 6
-
2025-521677-14-00
West Nile Virus Infection 4
-
2025-524363-20-01
HIV-1 infection 4
-
2024-519391-11-00
Respiratory viral disease 3
-
2023-504288-18-00
Chronic Hepatitis B 3
-
2024-517396-20-00
Sarbecoviruses disease 9
-
2026-525895-25-00
Acute infection 6
-
2023-504846-73-01
Glioblstoma WHO grade IV 4
-
2025-522348-42-00
post-COVID syndrome (long COVID) 9
-
2025-522349-23-00
post-COVID syndrome 5
-
2025-524443-12-00
Post Covid Syndrome (PCS) 4
-
2024-513941-35-00
HIV Disease 9
-
2023-509048-80-01
The present Phase 2 clinical study will evaluate the sa 4
-
2024-511054-50-00
HIV-1 Infection 10